Company: NCEL
Filing Date: 2025-09-19
Form Type: 6-K
Source: 0001213900-25-089523
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-09-19
Form: 6-K
Chunk 1
---
 of Regulation S-K and the related instructions) between the Company and Marcum on any matter of
accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved
to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreement in its reports on
the Company’s financial statements and (ii) except for the material weaknesses in the Company’s internal control over financial
reporting relating to a lack of sufficient number of trained professionals with an appropriate level of accounting knowledge to design
and maintain controls over the preparation of financial statements, and relating to a lack of maintaining appropriate segregation of
duties as disclosed in the Company’s annual report on Form 20-F for the year ended December 31, 2024, there were no “reportable
events” (as described in Item 16F(a)(1)(v) of Form 20-F).

During the fiscal year ended
December 31, 2024 and the subsequent interim period through September 17, 2025, neither the Company, nor anyone on its behalf,
consulted CBIZ regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the
type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided
to the Company by CBIZ that CBIZ concluded was an important factor considered by the Company in reaching a decision as to any accounting,
auditing or financial reporting issue or (ii) any matter that was the subject of a “disagreement” (as that term is defined
in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in
Item 304(a)(1)(v) of Regulation S-K).

<div align='center'>EXHIBIT INDEX</div>

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: September 19, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:-------------------------|:-----------------------|:--------------------|:------------------------|
|                          |                        | Name: